Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 1/2 dose-finding trial with modest sample size (116 completers) and short 12-week duration showing exploratory efficacy signals without major safety concerns, but requiring confirmation in phase 3 trials before clinical application.
Sound preclinical study in mice demonstrating metabolic benefit of a natural compound via plausible signaling pathways, but lacks human evidence and relies on surrogate endpoints and mechanistic markers rather than clinical outcomes.
Single-center animal study with mechanistic validation but no human data, uncontrolled design, and surrogate endpoints only; insufficient for clinical guidance despite sound experimental approach.